ebomi
Colour theme
Sign in
Insider · CIK 0001425738

Redmile Group, LLC

CIK 0001425738 Name as filed on the most recent filing

Filed as Redmile Group, LLC (46)

103 transaction lines · from 46 filings · filed 2015-08-10 to 2026-08-07 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

0 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2020-09-03 P, Open-market purchase IGM Biosciences, Inc.IGMS 3,615,208, acquired Open Form 4 filing 0001104659-20-102346
2020-09-02 P, Open-market purchase IGM Biosciences, Inc.IGMS 2 lines 963,267, acquired Open Form 4 filing 0001104659-20-102346
2020-09-01 P, Open-market purchase IGM Biosciences, Inc.IGMS 1,872,327, acquired Open Form 4 filing 0001104659-20-102346
2020-06-11 P, Open-market purchase Fate Therapeutics IncFATE 39,999,992, acquired Open Form 4 filing 0001104659-20-074301
2020-04-02 S, Open-market sale Neoleukin Therapeutics, Inc.NLTX 2 lines 111,214, disposed Open Form 4 filing 0001104659-20-043863
2020-04-02 P, Open-market purchase Neoleukin Therapeutics, Inc.NLTX 2 lines 446,958, acquired Open Form 4 filing 0001104659-20-043863
2020-04-01 S, Open-market sale Neoleukin Therapeutics, Inc.NLTX 2 lines 108,940, disposed Open Form 4 filing 0001104659-20-043863
2020-04-01 P, Open-market purchase Neoleukin Therapeutics, Inc.NLTX 2 lines 471,630, acquired Open Form 4 filing 0001104659-20-043863
2020-03-31 P, Open-market purchase Neoleukin Therapeutics, Inc.NLTX 2 lines 309,389, acquired Open Form 4 filing 0001104659-20-043863
2020-03-30 P, Open-market purchase Neoleukin Therapeutics, Inc.NLTX 2 lines 322,910, acquired Open Form 4 filing 0001104659-20-043863
2020-03-27 P, Open-market purchase Neoleukin Therapeutics, Inc.NLTX 460,395, acquired Open Form 4 filing 0001104659-20-043863
2019-10-07 P, Open-market purchase Aprea Therapeutics, Inc.APRE 6,000,000, acquired Open Form 4 filing 0001144204-19-047722
2019-09-16 P, Open-market purchase Fate Therapeutics IncFATE 15,000,003, acquired Open Form 4 filing 0001144204-19-044910
2019-02-19 P, Open-market purchase Xeris Pharmaceuticals IncXERS 5,880,000, acquired Open Form 4 filing 0001144204-19-009310
2018-09-25 P, Open-market purchase Fate Therapeutics IncFATE 50,000,004, acquired Open Form 4 filing 0001144204-18-051219
2018-06-25 P, Open-market purchase Xeris Pharmaceuticals IncXERS 10,000,020, acquired Open Form 4 filing 0001140361-18-030103
2016-09-28 S, Open-market sale Array Biopharma IncARRY 15,852,796, disposed Open Form 4 filing 0000919574-16-015622
2016-09-15 S, Open-market sale Array Biopharma IncARRY 25,842, disposed Open Form 4 filing 0000919574-16-015436
2016-09-15 P, Open-market purchase Array Biopharma IncARRY 98,000, acquired Open Form 4 filing 0000919574-16-015436
2016-09-14 S, Open-market sale Array Biopharma IncARRY 1,374,450, disposed Open Form 4 filing 0000919574-16-015436
2016-09-14 P, Open-market purchase Array Biopharma IncARRY 1,305,720, acquired Open Form 4 filing 0000919574-16-015436
2016-07-06 P, Open-market purchase Syros Pharmaceuticals, Inc.SYRS 4 lines 5,409,325, acquired Open Form 4 filing 0001104659-16-131410
2016-06-03 P, Open-market purchase Amicus Therapeutics IncFOLD 477,360, acquired Open Form 4 filing 0000919574-16-013646
2016-01-20 P, Open-market purchase Array Biopharma IncARRY 957,000, acquired Open Form 4 filing 0000919574-16-009564
2016-01-12 P, Open-market purchase Array Biopharma IncARRY 270,000, acquired Open Form 4 filing 0000919574-16-009285
2016-01-11 P, Open-market purchase Array Biopharma IncARRY 973,500, acquired Open Form 4 filing 0000919574-16-009138
2016-01-08 P, Open-market purchase Array Biopharma IncARRY 1,302,000, acquired Open Form 4 filing 0000919574-16-009138
2016-01-07 P, Open-market purchase Array Biopharma IncARRY 1,119,000, acquired Open Form 4 filing 0000919574-16-009138
2015-10-01 P, Open-market purchase Array Biopharma IncARRY 450,630, acquired Open Form 4 filing 0000919574-16-009136
2015-10-01 P, Open-market purchase Array Biopharma IncARRY 450,630, acquired Open Form 4 filing 0000919574-15-007132
2015-09-30 P, Open-market purchase Array Biopharma IncARRY 852,051, acquired Open Form 4 filing 0000919574-16-009136
2015-09-30 P, Open-market purchase Array Biopharma IncARRY 852,051, acquired Open Form 4 filing 0000919574-15-007132
2015-09-29 P, Open-market purchase Array Biopharma IncARRY 1,448,019, acquired Open Form 4 filing 0000919574-16-009136
2015-09-29 P, Open-market purchase Array Biopharma IncARRY 2,280,000, acquired Open Form 4 filing 0000919574-15-007132
2015-08-26 P, Open-market purchase Array Biopharma IncARRY 273,452, acquired Open Form 4 filing 0000919574-15-006617
2015-08-25 P, Open-market purchase Array Biopharma IncARRY 1,199,000, acquired Open Form 4 filing 0000919574-15-006489
2015-08-24 P, Open-market purchase Array Biopharma IncARRY 2,181,200, acquired Open Form 4 filing 0000919574-15-006489
2015-08-21 P, Open-market purchase Array Biopharma IncARRY 872,000, acquired Open Form 4 filing 0000919574-15-006489
2015-08-12 P, Open-market purchase Array Biopharma IncARRY 1,215,650, acquired Open Form 4 filing 0000919574-15-006007
2015-08-11 P, Open-market purchase Array Biopharma IncARRY 1,915,875, acquired Open Form 4 filing 0000919574-15-006007

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.

How to cite this page

ebomi catalog. Redmile Group, LLC, insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001425738

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.